We studied the in vitro activity of gemifloxacin (SB-265805) and 14 comparator antimicrobials against 288 recent isolates of enteropathogenic bacteria (106 Salmonella spp., 32 Hafnia alvei, 22 Yersinia enterocolitica, 21 Shigella spp., 16 Aeromonas spp. and 91 Campylobacter jejuni). Gemifloxacin, the other fluoroquinolones and cefotaxime were very active against all microorganisms tested except for C. jejuni. Seventy-seven per cent of isolates of C. jejuni were inhibited by erythromycin 0.5 mg/L. Only one strain of C. jejuni was highly resistant to this antimicrobial agent. Of the compounds tested, gentamicin was the most active in vitro. The in vitro activity of the other antibiotics tested was variable. A quinolone could be a good choice for treating gastrointestinal infections when antimicrobial therapy is indicated. For C. jejuni, another antibiotic such as erythromycin should be considered. <
Introduction
Gemifloxacin (SB-265805) is a novel quinolone agent with a broad spectrum of antibacterial activity, including against both Gram-negative and Gram-positive microorganisms. Classical oral antimicrobial agents used against enteropathogenic bacterial isolates have recently demonstrated poor in vitro activity; [1] [2] [3] [4] this prompted us to test a range of antimicrobial agents against these organisms. Here, the in vitro activity of gemifloxacin and 14 other antimicrobials against recognized bacterial enteric pathogens and Hafnia alvei-a bacterium with possible enteric pathogenic capacity 5 -is compared.
Materials and methods

Bacterial strains
Two hundred and eighty-eight recent isolates of enteropathogenic bacterial isolates from patients with acute gastroenteritis were studied, including 106 Salmonella spp. Campylobacter jejuni. The strains were stored in skimmed milk at -80°C until studied. All infections were community acquired in Spain. None of the isolates was known to have been obtained from cases of travellers' diarrhoea.
Antimicrobials
The antibiotics tested were gemifloxacin, trovafloxacin, grepafloxacin, ciprofloxacin, ofloxacin, norfloxacin, levofloxacin, nalidixic acid, amoxycillin, cefotaxime, gentamicin, doxycycline, colistin, co-trimoxazole and, for C. jejuni, erythromycin. Each was provided as a powder of known potency by SmithKline Beecham Pharmaceuticals, Harlow, UK.
Antimicrobial susceptibility tests
MICs were determined by an agar dilution method 6 on Mueller-Hinton agar (Difco Laboratories, Detroit, MI, USA) supplemented with 5% sheep blood for C. jejuni isolates. The plates were incubated aerobically at 35°C for 24 h, except for C. jejuni, where a microaerophilic atmosphere was obtained by using Campy Pack (Becton Dickinson, Cockeysville, MD, USA). Incubation was for 48 h. All organisms were tested with an inoculum of c. 10 4 cfu/spot. Dilutions tested ranged from 0.015 to 128 mg/L. MICs were defined as the lowest antimicrobial concentration at which there was no visible growth. Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853 were used as controls. The antimicrobial susceptibility breakpoints 3, 6 used to define the percentage of susceptible isolates were as follows: erythromycin, 0.5 mg/L; grepafloxacin and ciprofloxacin, 1 mg/L; colistin, co-trimoxazole, ofloxacin and levofloxacin, 2 mg/L; norfloxacin, gentamicin and doxycycline, 4 mg/L; amoxycillin and cefotaxime, 8 mg/L; and nalidixic acid, 16 mg/L. For comparison purposes the chosen breakpoint for susceptibility of gemifloxacin and trovafloxacin was 1 mg/L. Table I shows the activity of gemifloxacin and the other antimicrobials tested against 288 enteropathogenic bacterial strains. Fluoroquinolones were very active against all microorganisms except for C. jejuni, where only 32% of Table II shows MICs of the quinolones studied against six isolates of Salmonella spp., for which the MICs of ciprofloxacin were у0.25 mg/L. Gentamicin was the most active antimicrobial tested, with only 4% of isolates of Salmonella spp. being resistant to it. Colistin was active against Y. enterocolitica, Shigella spp. and Aeromonas spp. Only 32% of Salmonella isolates were susceptible to colistin and its activity was also poor against H. alvei and C. jejuni. Cotrimoxazole was very active against all species studied, except for Shigella spp., with only 4% of Salmonella spp. and C. jejuni being resistant to this antibiotic. Doxycycline was very active against Aeromonas spp.; its activity against the other organisms tested was variable, with 40% of C. jejuni, 43% of Shigella spp., 78% of Salmonella spp., 78% of H. alvei and 95% of Y. enterocolitica isolates being susceptible to it.
Results
1024
Seventy-seven per cent of isolates of C. jejuni were inhibited by erythromycin р0.5 mg/L. Only one isolate was highly resistant to this antimicrobial (MIC 128 mg/L); the other isolates were all inhibited by erythromycin р4 mg/L. By weight, gemifloxacin was the most active compound tested, with 100% of isolates of each species, except for C. jejuni, being inhibited by a concentration of 0.25 mg/L.
Discussion
Antimicrobials may be useful for treating some cases of bacterial diarrhoea and for preventing this illness and the further spread of infection. 7 Since 1988, an increase in the resistance of Salmonella spp. to classical antimicrobials such as ampicillin, chloramphenicol, tetracycline and co-trimoxazole has been described, especially among S. typhimurium and S. virchow. 2, 3, 8 Our results confirm this, with rates of non-susceptibility of Salmonella spp. to amoxycillin, doxycycline and co-trimoxazole of 23, 22 and 4%, respectively. MICs of ciprofloxacin of у0.25 mg/L against Salmonella spp. isolates are considered by some authors as being of therapeutic relevance. 8 Six isolates of S. virchow, S. hadar, S. tshiongwe and S. newport with MICs of ciprofloxacin of у0.25 mg/L were studied. Gemifloxacin was the most active quinolone against these isolates (Table II) . Many Shigella spp. are resistant to aminopenicillins, co-trimoxazole and doxycycline, 3 as confirmed by our results, with high rates of resistance in these species to these three antimicrobials. H. alvei, in which virulence factors similar to those found in some phenotypes of E. coli have been described, 5 is usually susceptible to quinolones, newer cephalosporins, carbapenems and piperacillin. Our data suggest that a quinolone, cefotaxime, gentamicin and co-trimoxazole and, to a lesser extent, doxycycline, could be useful in the treatment of infections caused by this microorganism. Our data confirmed the good activity of quinolones, doxycycline, co-trimoxazole, gentamicin and cefotaxime and the inefficacy of aminopenicillins against Aeromonas spp.
9 Y. enterocolitica produces -lactamases that inactivate some -lactams and resistance to other antibiotics has also been described. 4 The antibiotics we tested, with the exception of amoxycillin, were very active against this microorganism.
High rates of resistance among C. jejuni strains are being described to quinolones, 1,3 but erythromycin and other macrolides are active against this microorganism. The quinolone resistance in C. jejuni found in our study is higher than that reported in 1996. 3 In contrast, only one isolate (1.1%) of C. jejuni showed high resistance to erythromycin. The high rates of quinolone-resistant C. jejuni in Spain seem to be associated with the massive use of these antibiotics, especially in animals. 10 In conclusion, quinolones can be good choices for treat- 
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